Person:
ZORLU, MEHMET

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
MEHMET
Last Name
ZORLU
Name
Email Address
Birth Date

Filters

2013 - 2019252020 - 20224
Reset filters

Settings

Author: KARATOPRAK, CUMALİ ×

Search Results

Now showing 1 - 10 of 29
  • Thumbnail Image
    PublicationOpen Access
    Assessment of serum endocan levels in patients with beta-thalassemia minor
    (2022-02-01T00:00:00Z) Zorlu, Mehmet; Ozer, Ömer Faruk; Karatoprak, Cumali; Kıskaç, Muharrem; Çakırca, Mustafa; ZORLU, MEHMET; ÖZER, ÖMER FARUK; KARATOPRAK, CUMALİ
    Objective: Beta-thalassemia minor is a blood disease caused by a hereditary decrease in beta-globin synthesis, frequently leading to hypochromic microcytic anemia. Formerly called endothelial cell-specific molecule 1, endocan is a proteoglycan released by vascular endothelial cells in many organs. Our aim was to investigate the relationship between the beta-thalassemia minor patients and the healthy control group in terms of serum endocan level. Methods: The study was performed in a total of 80 subjects. They were divided into two groups, the beta-thalassemia minor group (n=40) and the healthy control group (n=40). Serum endocan levels, age, sex, body mass index value, and tobacco use data of these groups were compared. Results: No statistically significant difference was detected between the two groups in terms of age, sex, and body mass index values (p>0.05). Endocan levels were measured to be 206.85±88.1 pg/mL in the beta-thalassemia minor group and 236.1±162.8 pg/mL in the control group with no significant difference between the groups in terms of serum endocan levels (p>0.05). Conclusions: In our study, there was no change in endocan level in beta-thalassemia minor. This might be because serum endocan levels are affected by multi-factorial reasons. Serum endocan levels may be altered secondarily to decreased beta-globin chain, increased sympathetic activity due to anemia, or platelet dysfunction induced by oxidative stress in beta-thalassemia minor. Further multicenter studies involving more patients are necessary to demonstrate this.
  • Thumbnail Image
    PublicationOpen Access
    CD40 ligand and P-selectin in heterozygous Beta-thalassemia
    (2016-06-01) CIKRIKCIOGLU, Mehmet Ali; SOYTAS, Rabia Bag; KILIC, Elif; Toprak, Aybala Erek; Karatoprak, CUMALİ; Zorlu, MEHMET; Kiskac, MUHARREM; EMEGIL, Sebnem; Cetin, GÜVEN; Dogan, ELİF ECE; SEKIN, Yahya; HAMDARD, Jamshid; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; KISKAÇ, MUHARREM; ÇETİN, GÜVEN; DOĞAN, ELİF ECE; KARATOPRAK, CUMALİ
    Objective: To investigate platelet functions and measure soluble CD40 ligand, soluble P-selectin, beta-thromboglobulin and platelet factor 4 levels in the blood of heterozygous beta thalassemia patients. Methods: The cross-sectional case-control study was conducted at Bezmialem Vakif University, Istanbul, Turkey, between September 2013 and April 2014, and comprised heterozygous beta thalassemia patients who were compared with 41 gender-, age- and body mass index-matched controls for platelet function markers. The two groups were also compared for co-morbidities, smoking, and regular medications. Results: Of the 78(78.78) subjects, 50(64%) were women and 28(36%) men with an overall mean age of 39.4±12.7 years (range: 18-79 years). The mean body mass index was 26.3±4.2. The heterozygous beta thalassemia group included 37(47%) subjects [24(65%) females; 13(35%) males] while the control group had 41(53%) [26(63%) females; 15(37%) males]. Soluble CD40 ligand and soluble P-selectin were lower in the heterozygous beta thalassemia group (p=0.009; p=0.010). Beta-thromboglobulin and platelet factor 4 levels were comparable between the groups (p=0.497; p=0.507.). Conclusions: Some platelet functions may be reduced in heterozygous beta thalassemia patients, which may be related to their lower incidence of cerebral and cardiac ischaemic events.
  • Thumbnail Image
    PublicationOpen Access
    Serum endocan levels in women with restless legs syndrome.
    (2015-11-19) CELIK, K; ÇıKRıKÇıOĞLU, MA; HALAC, G; KILIC, ERDEM; AYHAN, S; OZARAS, N; Karatoprak, CUMALİ; YILDIZ, KEMALETTİN; YILDIZ, RS; ZORLU, MEHMET; CAKIRCA, MUSTAFA; KıSKAÇ, MUHARREM; KILIÇ, ERDEM; YILDIZ, KEMALETTİN; ZORLU, MEHMET; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; KISKAÇ, MUHARREM
    Background: Endocan is a recently introduced marker of endothelial dysfunction. The objective of this study was to compare serum endocan levels in patients with restless legs syndrome (RLS) and control subjects in order to elucidate whether RLS is associated with endothelial dysfunction. Methods: A total of 31 drug naïve female patients with RLS and 31 age- and BMI-matched women were included in the study. Patients with pathological or physiological conditions or with a history of medication use that could potentially influence endothelial functions were excluded, as well as those with alcohol or drug abuse history. The two groups were compared with routine blood tests and serum endocan levels. Results: Patients with RLS had lower serum endocan levels than the controls (P=0.037). There was a negative bivariate correlation between RLS severity score and serum endocan levels (r=-0.406, P=0.023). While white blood cell count was significantly higher in RLS group, 25-hydroxy vitamin D3, vitamin B12, transferrin saturation rate, and HDL-cholesterol were significantly lower. Creatininemia and diastolic blood pressure were also marginally insignificantly lower in RLS group. Due to the presence of differences between two groups in these variables, a linear regression analysis was performed that showed a positive association between endocan and creatininemia (β=0.310, P=0.022), and a negative association between endocan and RLS (β=-0.502, P,0.001). Conclusion: The results of this study seem to suggest that patients with RLS may have better endothelial functions when compared with the general population and that these patients may be better protected against atherosclerosis
  • No Thumbnail Available
    PublicationMetadata only
    Evaluation of the relationship between vitamin D level and adropin, IL-1β, IL-6, and oxidative status in women
    (2022-01-01T00:00:00Z) ZORLU, MEHMET; ŞEKERCİ, ABDÜSSELAM; TUNÇ, MUHAMMED; Güler, Eray Metin; Gülen, Bedia; KARATOPRAK, CUMALİ; KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; ŞEKERCİ, ABDÜSSELAM; TUNÇ, MUHAMMED; KARATOPRAK, CUMALİ; KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFA
    Background: Vitamin D, adropin, proinflammatory cytokines, and oxidative stress closely related with metabolic homeostasis and endothelial dysfunction. The aim of the present study is to investigate how vitamin D levels affect serum adropin, IL-1ß, IL-6, and oxidative stress. Methods: A total of 77 female subjects were divided into 3 groups according to vitamin D levels. Biochemical parameters, adropin, IL-1ß, IL-6, oxidative stress markers were studied in these groups, and the results were compared statistically. Results: Serum adropin, IL-1ß, IL-6, total oxidant status (TOS) and total antioxidant status (TAS) and oxidative stress index (OSI) levels differed significantly between the vitamin D groups (p < 0.05). A significant positive correlation was detected between vitamin D, and adropin and TAS (r = 0.807; p < 0.001, r = 0.814; p < 0.001, respectively). A significant negative correlation was detected between vitamin D, and IL-1ß, IL-6, TOS, OSI (r = -0.725; p < 0.001, r = -0.720; p < 0.001, r = -0.238; p = 0.037, r = -0.705; p < 0.001, respectively). Discussion: Vitamin D could show its effects through vitamin D receptors on tissues or on the ENHO gene in adropin secreting tissues via direct or indirect mechanisms. Proinflammatory cytokines, oxidative stress, and adropin targeted studies could contribute to the prevention and treatment of diseases associated with vitamin D deficiency in future.
  • Thumbnail Image
    PublicationOpen Access
    Association of calcium channel blocker use with lower hemoglobin levels in chronic kidney disease
    (2013-09-01) Karatoprak, CUMALİ; CIKRIKCIOGLU, M. A.; Cakirca, MUSTAFA; Kiskac, MUHARREM; Zorlu, MEHMET; Cetin, GÜVEN; YILDIZ, KEMALETTİN; ERKOC, R.; ALAY, M.; Erkal, S.; Erkal, S. N.; DOGAN, S.; Kazancioglu, RÜMEYZA; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; KISKAÇ, MUHARREM; ZORLU, MEHMET; ÇETİN, GÜVEN; YILDIZ, KEMALETTİN; KAZANCIOĞLU, RÜMEYZA
    Aim: To search whether calcium channel blockers (CCBs) are associated with lower hemoglobin levels in chronic kidney disease (CKD) patients who are not on renal replacement therapy (RRT), vitamin D and anti-anemic treatment. Patients and methods: CKD patients were classified into two groups. Patients on CCBs treatment (103 patients) and patients not using CCBs (104 patients) were compared cross-sectionally regarding clinical findings, complete blood count (CBC), biochemistry and regular medication use. Patients with polycystic kidney disease, comorbidities that could influence CBC other than iron deficiency of obscure origin, patients receiving RRT, erythropoietin (EPO), vitamin D, phosphate binders and drugs that could influence CBC were excluded. Under dependent variable of CCB use, all significantly different independent variables were subjected to multivariate binary logistic regression analysis (MBLRA). Results: Lower hemoglobin, lower bilirubinemia, higher serum EPO, higher systolic blood pressure were observed in CCB users. Two groups were similar concerning age, gender, BMI, CKD etiology, CKD stage, pretibial edema prevalence, cardiothoracic index, diastolic blood pressure, corrected reticulocyte count, BUN, creatinine, eGFR, proBNP, parathormone, alkaline phosphatase, phosphorous, corrected calcemia, sCRP, relative EPO deficiency and prevalence of relative EPO deficient patients. Groups were comparable regarding comorbidities, types and usage frequencies of all antihypertensive medications other than CCBs. Higher systolic blood pressure and lower hemoglobin were significantly associated with CCB use after MBLRA. Conclusions: Hemoglobin was significantly lower in CCB users compared to non-users, among CKD patients who did not receive RRT, EPO, phosphate binders, vitamin D, iron, vitamin B12 and folic acid.
  • Thumbnail Image
    PublicationOpen Access
    An Iron Deficiency Anemia Case That Came with Raw Rice Consumption
    (2015-02-01) ÇAMLI, AHMET ADİL; KARATOPRAK, CUMALİ; ÇETİN, GÜVEN; ZORLU, MEHMET; ALAY, MURAT; ÇAMLI, AHMET ADİL; KARATOPRAK, CUMALİ; ÇETİN, GÜVEN; ZORLU, MEHMET
    Pica is the chronic consumption of edible or nonedible materials that is thought to be caused by mental problems, pregnancy, or anemia. We wanted to report this case, which we have not seen in the literature before, of a pica patient who consumed raw rice due to iron deficiency anemia. A 26-year-old female patient was brought to the internal medicine polyclinic by her mother with complaints of consuming a bowl of raw rice (200 gr) every evening. The patient was treated with parenteral ferik hydroxide + sucrose complex (2700 mg) for 5 days. After 15 days, when she came to control her will to eat raw rice had been lost completely. As a result, the attention of doctors and family members for pica due to treatable causes, such as anemia, will prevent many probable complications.
  • No Thumbnail Available
    PublicationMetadata only
    A case of rhabdomyolysis complicated with acute renal failure after resumption of fenofibrate therapy: a first report.
    (2013-05-01) KıSKAÇ, MUHARREM; ZORLU, MEHMET; CAKIRCA, MUSTAFA; Karatoprak, CUMALİ; PERU, C; ERKOÇ, R; YAVUZ, E; KISKAÇ, MUHARREM; ZORLU, MEHMET; ÇAKIRCA, MUSTAFA; KARATOPRAK, CUMALİ
  • No Thumbnail Available
    PublicationMetadata only
    Tekrarlayan piyüri ile gelen ve ailevi akdeniz ateşi tanısı konulan olgu sunumu
    (2014-10-19) KARATOPRAK, CUMALİ; ERKOÇ, REHA; ÇIKRIKÇIOĞLU, MEHMET ALİ; KISKAÇ, MUHARREM; ZORLU, MEHMET; ÇAKIRCA, MUSTAFA; ÇETİN, GÜVEN; KAZANCIOĞLU, RUMEYZA; KARATOPRAK, CUMALİ; KISKAÇ, MUHARREM; ZORLU, MEHMET; ÇAKIRCA, MUSTAFA; ÇETİN, GÜVEN
  • No Thumbnail Available
    PublicationMetadata only
    Pott-s disease and hypercalcemia in a patient with rheumatoid arthritis receiving methotrexate monotherapy
    (2013-11-01) KARATOPRAK, CUMALİ; ZORLU, MEHMET; KıSKAÇ, MUHARREM; CAKIRCA, MUSTAFA; YAVUZ, E; Cetin, GÜVEN; CIKRIKCIOGLU, MA; ZORLU, MEHMET; KISKAÇ, MUHARREM; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; ÇETİN, GÜVEN
  • No Thumbnail Available
    PublicationMetadata only
    Effects of 18-Month Vildagliptin Treatment on Portal Vein Pressure
    (2015-06-01) Karatoprak, CUMALİ; KILICARSLAN, Rukiye; Cakirca, MUSTAFA; Aydin, SİNEM; OZKAN, Tuba; KOCAMAN, Orhan; YOLBAS, Servet; Zorlu, MEHMET; Kiskac, MUHARREM; CIKRIKCIOGLU, Mehmet Ali; KOCAKOC, Ercan; ERKOC, Reha; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; AYDIN, SİNEM; ZORLU, MEHMET; KISKAÇ, MUHARREM